Background: The PLASMIC score is a rapid and inexpensive tool for predicting severe ADAMTS13 deficiency (activity <10%) in patients with suspected thrombotic thrombocytopenic purpura (TTP) by analyzing seven parameters (platelet count; combined hemolysis variable; absence of active neoplasia; absence of an organ or stem-cell transplant; mean corpuscular value; international normalized ratio; and serum creatinine). The purpose of this study was to validate the PLASMIC score at a large multi-institutional academic medical center.
Methods: An internal database of consultations to the transfusion medicine service, which oversees therapeutic apheresis at our institution, was reviewed to identify patients who were evaluated for and/or received plasma exchange for suspected TTP.
Objectives: To conduct a clinicopathologic study of male breast carcinoma with Magee equation recurrence score (RS).
Methods: Seventy-four cases of male invasive breast cancers (MBCs) were studied, including 63 hormone receptor (HR)-positive, 10 human epidermal growth factor receptor 2-positive, and one triple-negative breast cancers.
Results: Among 63 HR-positive MBC patients, nine patients developed distal metastasis.